Tibolone

Tibolone, sold under the brand names Livial and Tibofem among others, is a medication which is used in menopausal hormone therapy and in the treatment of postmenopausal osteoporosis and endometriosis.[1][7][8][9] The medication is available alone and is not formulated or used in combination with other medications.[10] It is taken by mouth.[1]

Tibolone
Clinical data
Trade namesLivial, Tibofem, others
Other namesTIB; ORG-OD-14; 7α-Methylnoretynodrel; 7α-Methyl-17α-ethynyl-19-nor-δ5(10)-testosterone; 17α-Ethynyl-7α-methylestr-5(10)-en-17β-ol-3-one; 7α-Methyl-19-nor-17α-pregn-5(10)-en-20-yn-17-ol-3-one
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  • ADEC Category D
Routes of
administration		By mouth[1]
Drug classProgestogen; Progestin; Estrogen; Androgen; Anabolic steroid
ATC code
Legal status
Legal status
  • CA: Schedule IV[2]
Pharmacokinetic data
Bioavailability92%[3]
Protein binding96.3% (to albumin; low affinity for SHBG)[3]
MetabolismLiver, intestines (hydroxyl-ation, isomerization, conjugation)[1][4]
Metabolites• Δ4-Tibolone[5]
• 3α-Hydroxytibolone[5]
• 3β-Hydroxytibolone[5]
• Sulfate conjugates[6]
Elimination half-life45 hours[4]
ExcretionUrine: 40%[3]
Feces: 60%[3]
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.024.609
Chemical and physical data
FormulaC21H28O2
Molar mass312.446 g/mol g·mol−1
3D model (JSmol)
  (verify)

Side effects of tibolone include acne and increased hair growth among others.[4] Tibolone is a synthetic steroid with weak estrogenic, progestogenic, and androgenic activity, and hence is an agonist of the estrogen, progesterone, and androgen receptors.[11][1][4][5] It is a prodrug of several metabolites.[1][11][12] The estrogenic effects of tibolone are selective to certain tissues, with such effects in bone, the vagina, and the brain, but not in the uterus, breast, or liver.[11][13][12][14]

Tibolone was developed in the 1960s and was introduced for medical use in 1988.[15][16] It is marketed widely throughout the world, for instance in Europe.[10][17] The medication is notably not available in the United States or Canada.[10][17] It is a controlled substance in Canada, with the classification of an anabolic steroid.[2]

Medical uses

Tibolone is used in the treatment of menopausal symptoms like hot flashes and vaginal atrophy, postmenopausal osteoporosis, and endometriosis.[1][18][9] It has similar or greater effectiveness compared to older menopausal hormone therapy medications, but shares a similar side effect profile.[19][20][21] It has also been investigated as a possible treatment for female sexual dysfunction.[22]

Tibolone reduces hot flashes, prevents bone loss, improves vaginal atrophy and urogenital symptoms (e.g., vaginal dryness, dyspareunia), and has positive effects on mood and sexual function.[23][20][24] The medication may have greater benefits on libido than standard menopausal hormone therapy, which may be related to its androgenic effects.[20][24] It does not cause increased endometrial proliferation and is associated with low rates of vaginal bleeding and breast pain.[23]

A 2015 network meta-analysis of randomized controlled trials found that tibolone was associated with a significantly decreased risk of breast cancer (RR = 0.317).[25] The decrease in risk was greater than that observed with most of the aromatase inhibitors and selective estrogen receptor modulators that were included in the analysis.[25] However, paradoxically, other research has found evidence supporting an increased risk of breast cancer with tibolone.[26][27]

Androgen replacement therapy formulations and dosages used in women
RouteMedicationMajor brand namesFormDosage
OralTestosterone undecanoateAndriol, JatenzoCapsule40–80 mg 1x/1–2 days
MethyltestosteroneMetandren, EstratestTablet0.5–10 mg/day
FluoxymesteroneHalotestinTablet1–2.5 mg 1x/1–2 days
NormethandroneaGinecosideTablet5 mg/day
TiboloneLivialTablet1.25–2.5 mg/day
Prasterone (DHEA)b–Tablet10–100 mg/day
SublingualMethyltestosteroneMetandrenTablet0.25 mg/day
TransdermalTestosteroneIntrinsaPatch150–300 μg/day
AndroGelGel, cream1–10 mg/day
VaginalPrasterone (DHEA)IntrarosaInsert6.5 mg/day
InjectionTestosterone propionateaTestovironOil solution25 mg 1x/1–2 weeks
Testosterone enanthateDelatestryl, Primodian DepotOil solution25–100 mg 1x/4–6 weeks
Testosterone cypionateDepo-Testosterone, Depo-TestadiolOil solution25–100 mg 1x/4–6 weeks
Testosterone isobutyrateaFemandren M, FolivirinAqueous suspension25–50 mg 1x/4–6 weeks
Mixed testosterone estersClimacteronaOil solution150 mg 1x/4–8 weeks
Omnadren, SustanonOil solution50–100 mg 1x/4–6 weeks
Nandrolone decanoateDeca-DurabolinOil solution25–50 mg 1x/6–12 weeks
Prasterone enanthateaGynodian DepotOil solution200 mg 1x/4–6 weeks
ImplantTestosteroneTestopelPellet50–100 mg 1x/3–6 months
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template.

Available forms

Tibolone is available in the form of 2.5 mg oral tablets.[28] It is typically used once daily at a dosage of 1.25 or 2.5 mg.[28]

Side effects

A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen, raloxifene, and tibolone used to reduce the risk of breast cancer significantly reduce the occurrence of invasive breast cancer in midlife and older women, but also increase the risk of adverse effects.[29]

Tibolone can infrequently produce androgenic side effects such as acne and increased facial hair growth.[4] Such side effects have been found to occur in 3 to 6% of treated women.[4]

A 2016 Cochrane review has been published on the short-term and long-term effects of tibolone, including adverse effects.[30] Possible adverse effects of tibolone include unscheduled vaginal bleeding (OR = 2.79; incidence 13–26% more than placebo), an increased risk of breast cancer in women with a history of breast cancer (OR = 1.5) although apparently not without a history of breast cancer (OR = 0.52), an increased risk of cerebrovascular events (strokes) (OR = 1.74) and cardiovascular events (OR = 1.38), and an increased risk of endometrial cancer (OR = 2.04).[30] However, most of these figures are based on very low-quality evidence.[30]

Pharmacology

Pharmacodynamics
Δ4-Tibolone, one of the active metabolites of tibolone.

Tibolone possesses a complex pharmacology and has weak estrogenic, progestogenic, and androgenic activity.[4][1][5] Tibolone, 3α-hydroxytibolone, and 3β-hydroxytibolone act as agonists of the estrogen receptors.[1][5] Tibolone and its metabolite δ4-tibolone act as agonists of the progesterone and androgen receptors,[31] while 3α-hydroxytibolone and 3β-hydroxytibolone, conversely, act as antagonists of these receptors.[5] Relative to other progestins, tibolone, including its metabolites, has been described as possessing moderate functional antiestrogenic activity (that is, progestogenic activity), moderate estrogenic activity, high androgenic activity, and no clinically significant glucocorticoid, antiglucocorticoid, mineralocorticoid, or antimineralocorticoid activity.[1][32] The ovulation-inhibiting dosage of tibolone is 2.5 mg/day.[1]

Relative affinities (%) of noretynodrel, tibolone, and metabolites
CompoundCode namePRARERGRMRSHBGCBG
Noretynodrel–6020000
  Norethisterone (δ4-NYD)–67–751500–10–3160
  3α-Hydroxynoretynodrel–???????
  3β-Hydroxynoretynodrel–???????
  Ethinylestradiol–15–251–31121–3<10.18<0.1
Tibolone (7α-Me-NYD)ORG-OD-14661????
  Δ4-TiboloneORG-OM-38903510210
  3α-HydroxytiboloneORG-4094034–60???
  3β-HydroxytiboloneORG-301260043–290???
  7α-Methylethinylestradiol–???????
Notes: Values are percentages (%). Reference ligands (100%) were promegestone for the PR, metribolone for the AR, E2 for the ER, DEXA for the GR, aldosterone for the MR, DHT for SHBG, and cortisol for CBG. Sources: See template.
Absolute activities (nM) of tibolone and metabolites
CompoundCode namePRARERαERβGRMR
TiboloneORG-OD-141231.0541052410*170*
Δ4-TiboloneORG-OM-38460.2263001760*30*
3α-HydroxytiboloneORG-40942400*135*1.7100ND*1160*
3β-HydroxytiboloneORG-3012620000*ND*2.4115ND*3310*
Notes: Values are affinities (nM). Non-italicized values are EC50. Italicized values with an asterisk (*) are IC50. Reference ligands (EC50) were promegestone (5 nM for PR), metribolone (0.1 nM for AR), estradiol (0.018 nM for ERα, 0.08 nM for ERβ), dexamethasone (6 nM for GR), and aldosterone (0.36 nM for MR). Sources: See template.

Estrogenic activity

Tibolone and its two major active metabolites, 3α-hydroxytibolone and 3β-hydroxytibolone, act as potent, fully activating agonists of the estrogen receptor (ER), with a high preference for the ERα.[5][31][13] These estrogenic metabolites of tibolone have much weaker activity as estrogens than estradiol (e.g., have 3–29% of the affinity of estradiol for the ER), but occur at relatively high concentrations that are sufficient for full and marked estrogenic responses to occur.[1][13][33]

The estrogenic effects of tibolone show tissue selectivity, with desirable effects in bone, the brain, and the vagina, and lack of undesirable action in the uterus, breast, or liver.[13][11][12] This tissue selectivity is thought to be the result of metabolism, enzyme modulation (e.g., of estrogen sulfatase and estrogen sulfotransferase), and receptor modulation that vary in different target tissues, and differs mechanistically from that of selective estrogen receptor modulators (SERMs) such as tamoxifen, which produce their tissue selectivity via means of modulation of the ER.[31][13] As such, to distinguish it from SERMs, tibolone has been variously described as a "selective tissue estrogenic activity regulator" (STEAR),[13] "selective estrogen enzyme modulator" (SEEM),[14] or "tissue-specific receptor and intracrine mediator" (TRIM).[32] More encompassingly, tibolone has also been described as a "selective progestogen, estrogen, and androgen regulator" (SPEAR), which is meant to reflect the fact that it is tissue-selective and that it regulates effects not only of estrogens but of all three of the major sex hormone classes.[32]

It was reported in 2002 that tibolone or its metabolite δ4-tibolone is transformed by aromatase into the potent estrogen 7α-methylethinylestradiol in women, analogously to the transformation of norethisterone into ethinylestradiol.[34] Controversy and disagreement followed when other researchers contested the findings however.[35][36][37][38][39][40] By 2008, these researchers had asserted that tibolone is not aromatized in women and that the previous findings of 7α-methylethinylestradiol detection were merely a methodological artifact.[37][39][40] In accordance, a 2009 study found that an aromatase inhibitor had no effect on the estrogenic potencies of tibolone or its metabolites in vitro, unlike the case of testosterone.[5] In addition, another 2009 study found that the estrogenic effects of tibolone on adiposity in rats do not require aromatization (as indicated by the use of aromatase knockout mice), further in support that 3α-hydroxytibolone and 3β-hydroxytibolone are indeed responsible for such effects.[41] These findings are also in accordance with the fact that tibolone decreases sex hormone-binding globulin (SHBG) levels by 50% in women and does not increase the risk of venous thromboembolism (VTE) (RR = 0.92), which would not be expected if the medication formed a potent, liver metabolism-resistant estrogen similar to ethinylestradiol in important quantities.[1][42] (For comparison, combined oral contraceptives containing ethinylestradiol, due mostly or completely to the estrogen component, have been found to increase SHBG levels by 200 to 400% and to increase the risk of VTE by about 4-fold (OR = 4.03).)[43][44]

In spite of the preceding, others have held, as recently as 2011, that tibolone is converted into 7α-methylethinylestradiol in small quantities.[45][46] They have claimed that 19-nortestosterone derivatives like tibolone, due to lacking a C19 methyl group, indeed are not substrates of the classical aromatase enzyme, but instead are still transformed into the corresponding estrogens by other cytochrome P450 monooxygenases.[38][45][46] In accordance, the closely structurally related AAS trestolone (7α-methyl-19-nortestosterone or 17α-desethynyl-δ4-tibolone) has been found to be transformed into 7α-methylestradiol by human placental microsomes in vitro.[40][47] Also in accordance, considerably disproportionate formation of ethinylestradiol occurs when norethisterone is taken orally (and hence undergoes first-pass metabolism in the liver) relative to parenterally,[48][49] despite the absence of aromatase in the adult human liver.[46][50]

Progestogenic activity

Tibolone and δ4-tibolone act as agonists of the progesterone receptor (PR).[1][46][51] Tibolone has low affinity of 6% of that of promegestone for the PR, while δ4-tibolone has high affinity of 90% of that of promegestone for the PR.[1][46] In spite of its high affinity for the PR however, δ4-tibolone possesses only weak progestogenic activity, about 13% of that of norethisterone.[1][46] The weak progestogenic activity of tibolone may not be sufficient to fully counteract its estrogenic activity in the uterus and may be responsible for the 100 to 200% increased risk of endometrial cancer that has been observed with tibolone in women in large cohort studies.[1][46]

Androgenic activity

Tibolone, mainly via δ4-tibolone, has androgenic activity.[46][1] Whereas tibolone itself has only about 6% of the affinity of metribolone for the androgen receptor, δ4-tibolone has relatively high affinity of about 35% of the affinity of metribolone for this receptor.[46][1] At typical clinical dosages in women, the androgenic effects of tibolone are weak.[46][1] However, relative to other 19-nortestosterone progestins, the androgenic activity of tibolone is high, with a potency comparable to that of testosterone.[46][1] Indeed, the androgenic effects of tibolone have been ranked as stronger than those of all other commonly used 19-nortestosterone progestins (e.g., norethisterone, levonorgestrel, others).[46][1]

The androgenic effects of tibolone have been postulated to be involved in the reduced breast cell proliferation, reduced breast cancer risk, improvement in sexual function, less unfavorable changes in hemostatic parameters relative to estrogen–progestogen combinations, and changes in liver protein synthesis (e.g., 30% reductions in HDL cholesterol levels, 20% reduction in triglyceride levels, and 50% reduction in SHBG levels) observed with tibolone.[46][1] They are also responsible for the androgenic side effects of tibolone such as acne and increased hair growth in some women.[4]

Other activities

Tibolone, 3α-hydroxytibolone, and 3β-hydroxytibolone act as antagonists of the glucocorticoid and mineralocorticoid receptors, with preference for the mineralocorticoid receptor.[5] However, their affinities for these receptors are low, and tibolone has been described as possessing no clinically significant glucocorticoid, antiglucocorticoid, mineralocorticoid, or antimineralocorticoid activity.[1][32]

Pharmacokinetics
Tibolone metabolism.[6]

The mean oral bioavailability of tibolone is 92%.[3] Its plasma protein binding is 96.3%.[3] It is bound to albumin, and both tibolone and its metabolites have low affinity for SHBG.[3][1] Tibolone is metabolized in the liver and intestines.[1][4] It is a prodrug and is rapidly transformed into several metabolites, including δ4-tibolone, 3α-hydroxytibolone, and 3β-hydroxytibolone, as well as sulfate conjugates of these metabolites.[1][51][6] 3α-Hydroxytibolone is formed by 3α-hydroxysteroid dehydrogenase, 3β-hydroxytibolone is formed by 3β-hydroxysteroid dehydrogenase, δ4-tibolone is formed by Δ5-4-isomerase, and the sulfate conjugates of tibolone and its metabolites are formed by sulfotransferases, mainly SULT2A1.[32] [52] The sulfate conjugates can be transformed back into free steroids by steroid sulfatase.[53] Following a single oral dose of 2.5 mg tibolone, peak serum levels of tibolone were 1.6 ng/mL, of δ4-tibolone were 0.8 ng/mL, of 3α-hydroxytibolone were 16.7 ng/mL, and of 3β-hydroxytibolone were 3.7 ng/mL after 1 to 2 hours.[1] The elimination half-life of tibolone is 45 hours.[4] It is excreted in urine 40% and feces 60%.[3][4]

Chemistry
See also: List of progestogens, List of androgens/anabolic steroids, and List of estrogens

Tibolone, also known as 7α-methylnoretynodrel, as well as 7α-methyl-17α-ethynyl-19-nor-δ5(10)-testosterone or as 7α-methyl-17α-ethynylestr-5(10)-en-17β-ol-3-one, is a synthetic estrane steroid and a derivative of testosterone and 19-nortestosterone.[7][1] It is more specifically a derivative of norethisterone (17α-ethynyl-19-nortestosterone) and is a member of the estrane subgroup of the 19-nortestosterone family of progestins.[1][54][55][15] Tibolone is the 7α-methyl derivative of the progestin noretynodrel (17α-ethynyl-δ5(10)-19-nortestosterone).[1] Other steroids related to tibolone include the progestin norgesterone (17α-vinyl-δ5(10)-19-nortestosterone) and the anabolic steroids trestolone (7α-methyl-19-nortestosterone) and mibolerone (7α,17α-dimethyl-19-nortestosterone).[7]

History

Tibolone was developed in the 1960s.[15] It was first introduced in the Netherlands in 1988, and was subsequently introduced in the United Kingdom in 1991.[16][56]

Society and culture

Generic names

Tibolone is the generic name of the drug and its INN, USAN, BAN, DCF, and JAN.[7][8] It is also known by its developmental code name ORG-OD-14.[4]

Brand names

Tibolone is marketed under the brand names Livial, Tibofem, and Ladybon among others.[7][8][10]

Availability

Tibolone and is used widely in Europe, Asia, Australasia, and elsewhere in the world, but is notably not available in the United States or Canada.[10][17][57]

Tibolone is a Schedule IV controlled substance in Canada under the 1996 Controlled Drugs and Substances Act.[2] It is classified as an anabolic steroid under this act, due to its relatively high activity as an AR agonist, and is the only norethisterone (17α-ethynyl-19-nortestosterone) derivative that is classified as such.[2]

References
  1. Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
  2. "Controlled Drugs and Substances Act (S.C. 1996, c. 19)". 2016-11-30.
  3. "Tibolone 2.5 mg Tablets" (PDF). Public Assessment Report. United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA).
  4. Albertazzi P, Di Micco R, Zanardi E (1998). "Tibolone: a review". Maturitas. 30 (3): 295–305. doi:10.1016/S0378-5122(98)00059-0. PMID 9881330.
  5. Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, Maudelonde T (2009). "Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites". J. Steroid Biochem. Mol. Biol. 116 (1–2): 8–14. doi:10.1016/j.jsbmb.2009.03.008. PMID 19464167.
  6. Falany JL, Macrina N, Falany CN (April 2004). "Sulfation of tibolone and tibolone metabolites by expressed human cytosolic sulfotransferases". J. Steroid Biochem. Mol. Biol. 88 (4–5): 383–91. doi:10.1016/j.jsbmb.2004.01.005. PMID 15145448.
  7. Ganellin C, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 1974–. ISBN 978-0-412-46630-4.
  8. Morton I, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 275–. ISBN 978-94-011-4439-1.
  9. "Tibolone". AdisInsight.
  10. "Tibolone". Drugs.com.
  11. Cano A (2 November 2017). Menopause: A Comprehensive Approach. Springer. pp. 103–. ISBN 978-3-319-59318-0.
  12. Falcone T, Hurd WW (14 June 2017). Clinical Reproductive Medicine and Surgery: A Practical Guide. Springer. pp. 182–. ISBN 978-3-319-52210-4.
  13. Schneider HP, Naftolin F (22 September 2004). Climacteric Medicine - Where Do We Go?: Proceedings of the 4th Workshop of the International Menopause Society. CRC Press. pp. 126–. ISBN 978-0-203-02496-6.
  14. King T, Brucker MC (25 October 2010). Pharmacology for Women's Health. Jones & Bartlett Learning. pp. 371–. ISBN 978-0-7637-5329-0.
  15. Fritz MA, Speroff L (28 March 2012). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 769–. ISBN 978-1-4511-4847-3.
  16. de Vries CS, Bromley SE, Thomas H, Farmer RD (2005). "Tibolone and endometrial cancer: a cohort and nested case-control study in the UK". Drug Safety. 28 (3): 241–9. doi:10.2165/00002018-200528030-00005. PMID 15733028.
  17. Segal SJ, Mastroianni L (4 October 2003). Hormone Use in Menopause and Male Andropause : A Choice for Women and Men: A Choice for Women and Men. Oxford University Press, USA. pp. 73–. ISBN 978-0-19-803620-3.
  18. Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A (January 2009). Al Kadri H (ed.). "Hormone therapy for endometriosis and surgical menopause". The Cochrane Database of Systematic Reviews (1): CD005997. doi:10.1002/14651858.CD005997.pub2. PMID 19160262.
  19. Lazovic G, Radivojevic U, Marinkovic J (April 2008). "Tibolone: the way to beat many a postmenopausal ailments". Expert Opinion on Pharmacotherapy. 9 (6): 1039–47. doi:10.1517/14656566.9.6.1039. PMID 18377345.
  20. Garefalakis M, Hickey M (2008). "Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence". Clin Interv Aging. 3 (1): 1–8. doi:10.2147/CIA.S1043. PMC 2544356. PMID 18488873.
  21. Vavilis D, Zafrakas M, Goulis DG, Pantazis K, Agorastos T, Bontis JN (2009). "Hormone therapy for postmenopausal breast cancer survivors: a survey among obstetrician-gynaecologists". European Journal of Gynaecological Oncology. 30 (1): 82–4. PMID 19317264.
  22. Ziaei S, Moghasemi M, Faghihzadeh S (April 2010). "Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women". Climacteric. 13 (2): 147–56. doi:10.1080/13697130903009195. PMID 19731119.
  23. Kenemans P, Speroff L (May 2005). "Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group". Maturitas. 51 (1): 21–8. doi:10.1016/j.maturitas.2005.02.011. PMID 15883105.
  24. Davis SR (2002). "The effects of tibolone on mood and libido". Menopause. 9 (3): 162–70. doi:10.1097/00042192-200205000-00004. PMID 11973439.
  25. Mocellin S, Pilati P, Briarava M, Nitti D (February 2016). "Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials". J. Natl. Cancer Inst. 108 (2). doi:10.1093/jnci/djv318. PMID 26582062.
  26. Erel CT, Senturk LM, Kaleli S (October 2006). "Tibolone and breast cancer". Postgrad Med J. 82 (972): 658–62. doi:10.1136/pgmj.2005.037184. PMC 2653908. PMID 17068276.
  27. Wang PH, Cheng MH, Chao HT, Chao KC (June 2007). "Effects of tibolone on the breast of postmenopausal women". Taiwan J Obstet Gynecol. 46 (2): 121–6. doi:10.1016/S1028-4559(07)60005-9. PMID 17638619.
  28. Meeta (15 December 2013). Postmenopausal Osteoporosis: Basic and Clinical Concepts. Jaypee Brothers Publishers. pp. 117–. ISBN 978-93-5090-833-4.
  29. "Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects, New Report Says". U.S. Department of Health & Human Services - Agency for Healthcare Research and Quality. September 2009. Retrieved 2 June 2014.
  30. Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V, Marata AM, Magrini N, D'Amico R, Bassi C, Maestri E (October 2016). "Short-term and long-term effects of tibolone in postmenopausal women". Cochrane Database Syst Rev. 10: CD008536. doi:10.1002/14651858.CD008536.pub3. PMC 6458045. PMID 27733017.
  31. Falcone T, Hurd WW (22 May 2013). Clinical Reproductive Medicine and Surgery: A Practical Guide. Springer Science & Business Media. pp. 152–. ISBN 978-1-4614-6837-0.
  32. Purdie DW (September 2002). "What is tibolone--and is it a SPEAR?". Climacteric. 5 (3): 236–9. doi:10.1080/cmt.5.3.236.239. PMID 12419081.
  33. Schoonen WG, Deckers GH, de Gooijer ME, de Ries R, Kloosterboer HJ (2000). "Hormonal properties of norethisterone, 7α-methyl-norethisterone and their derivatives". J. Steroid Biochem. Mol. Biol. 74 (4): 213–22. doi:10.1016/s0960-0760(00)00125-4. PMID 11162927.
  34. Wiegratz I, Sänger N, Kuhl H (2002). "Formation of 7 alpha-methyl-ethinyl estradiol during treatment with tibolone". Menopause. 9 (4): 293–5. doi:10.1097/00042192-200207000-00011. PMID 12082366.
  35. de Gooyer ME, Oppers-Tiemissen HM, Leysen D, Verheul HA, Kloosterboer HJ (2003). "Tibolone is not converted by human aromatase to 7alpha-methyl-17alpha-ethynylestradiol (7alpha-MEE): analyses with sensitive bioassays for estrogens and androgens and with LC-MSMS". Steroids. 68 (3): 235–43. doi:10.1016/S0039-128X(02)00184-8. PMID 12628686.
  36. Raobaikady B, Parsons MF, Reed MJ, Purohit A (2006). "Lack of aromatisation of the 3-keto-4-ene metabolite of tibolone to an estrogenic derivative". Steroids. 71 (7): 639–46. doi:10.1016/j.steroids.2006.03.006. PMID 16712888.
  37. Zacharia LC, Jackson EK, Kloosterboer HJ, Imthurn B, Dubey RK (2006). "Conversion of tibolone to 7alpha-methyl-ethinyl estradiol using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry: interpretation and clinical implications". Menopause. 13 (6): 926–34. doi:10.1097/01.gme.0000227331.49081.d7. PMID 17006378.
  38. Kuhl H, Wiegratz I (2007). "Can 19-nortestosterone derivatives be aromatized in the liver of adult humans? Are there clinical implications?". Climacteric. 10 (4): 344–53. doi:10.1080/13697130701380434. PMID 17653961.
  39. Dröge MJ, Oostebring F, Oosting E, Verheul HA, Kloosterboer HJ (2007). "7alpha-Methyl-ethinyl estradiol is not a metabolite of tibolone but a chemical stress artifact". Menopause. 14 (3 Pt 1): 474–80. doi:10.1097/01.gme.0000247015.63877.d4. PMID 17237734.
  40. Kloosterboer HJ (2008). "Tibolone is not aromatized in postmenopausal women". Climacteric. 11 (2): 175, author reply 175–6. doi:10.1080/13697130701752087. PMID 18365860.
  41. Van Sinderen ML, Boon WC, Ederveen AG, Kloosterboer HJ, Simpson ER, Jones ME (2009). "The estrogenic component of tibolone reduces adiposity in female aromatase knockout mice". Menopause. 16 (3): 582–8. doi:10.1097/gme.0b013e31818fb20b. PMID 19182696.
  42. Renoux C, Dell'Aniello S, Suissa S (May 2010). "Hormone replacement therapy and the risk of venous thromboembolism: a population-based study". J. Thromb. Haemost. 8 (5): 979–86. doi:10.1111/j.1538-7836.2010.03839.x. PMID 20230416.
  43. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. pp. 157–. ISBN 978-92-832-1291-1.
  44. Heit JA, Spencer FA, White RH (2016). "The epidemiology of venous thromboembolism". J. Thromb. Thrombolysis. 41 (1): 3–14. doi:10.1007/s11239-015-1311-6. PMC 4715842. PMID 26780736.
  45. Kuhl H, Wiegratz I (2007). "In vivo conversion of TIB to MEE not an artifact generated by heat". Menopause. 14 (2): 331–4, author reply 334–5. doi:10.1097/01.gme.0000264447.18842.da. PMID 17496790.
  46. Kuhl H (2011). "Pharmacology of progestogens" (PDF). Journal für Reproduktionsmedizin und Endokrinologie-Journal of Reproductive Medicine and Endocrinology. 8 (Special Issue 1): 157–176.
  47. LaMorte A, Kumar N, Bardin CW, Sundaram K (February 1994). "Aromatization of 7 alpha-methyl-19-nortestosterone by human placental microsomes in vitro". J. Steroid Biochem. Mol. Biol. 48 (2–3): 297–304. doi:10.1016/0960-0760(94)90160-0. PMID 8142308.
  48. Kuhnz W, Heuner A, Hümpel M, Seifert W, Michaelis K (December 1997). "In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women". Contraception. 56 (6): 379–85. doi:10.1016/S0010-7824(97)00174-1. PMID 9494772.
  49. Friedrich C, Berse M, Klein S, Rohde B, Höchel J (June 2018). "In Vivo Formation of Ethinylestradiol After Intramuscular Administration of Norethisterone Enantate". J Clin Pharmacol. 58 (6): 781–789. doi:10.1002/jcph.1079. PMID 29522253.
  50. Hata S, Miki Y, Saito R, Ishida K, Watanabe M, Sasano H (June 2013). "Aromatase in human liver and its diseases". Cancer Med. 2 (3): 305–15. doi:10.1002/cam4.85. PMC 3699842. PMID 23930207.
  51. Verhoeven CH, Vos RM, Delbressine LP (2002). "The in vivo metabolism of tibolone in animal species". Eur J Drug Metab Pharmacokinet. 27 (1): 1–10. doi:10.1007/BF03190399. PMID 11996321.
  52. Wang M, Ebmeier CC, Olin JR, Anderson RJ (May 2006). "Sulfation of tibolone metabolites by human postmenopausal liver and small intestinal sulfotransferases (SULTs)". Steroids. 71 (5): 343–51. doi:10.1016/j.steroids.2005.11.003. PMID 16360722.
  53. Falany JL, Falany CN (2007). "Interactions of the human cytosolic sulfotransferases and steroid sulfatase in the metabolism of tibolone and raloxifene". J. Steroid Biochem. Mol. Biol. 107 (3–5): 202–10. doi:10.1016/j.jsbmb.2007.03.046. PMC 2697607. PMID 17662596.
  54. Pasqualini JR (17 July 2002). Breast Cancer: Prognosis, Treatment, and Prevention. CRC Press. pp. 222–. ISBN 978-0-203-90924-9.
  55. Yao AP (2005). Trends in Breast Cancer Research. Nova Publishers. pp. 58–. ISBN 978-1-59454-134-6.
  56. Berning B, Coelingh Bennink HJ, Fauser BC (2009). "Tibolone and its effects on bone: a review". Climacteric. 4 (2): 120–136. doi:10.1080/cmt.4.2.120.136.
  57. Goldstein I, Meston CM, Davis S, Traish A (17 November 2005). Women's Sexual Function and Dysfunction: Study, Diagnosis and Treatment. CRC Press. pp. 556–. ISBN 978-1-84214-263-9.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.